HealthTree Logo
search more_vert
person Sign In / Create Account
Natural Killer Cells Can Be Used With Standard Myeloma Therapies
Posted: Feb 07, 2017
Natural Killer Cells Can Be Used With Standard Myeloma Therapies image

The main function of natural killer (NK) cells is to destroy cells that are virally infected, damaged or transformed. Some research suggests that some myeloma drugs like lenalidomide and bortezomib may enhance these NK cells, which is why they help kill myeloma cells.

Researchers wonder:

  • If NK cells can be used after stem cell transplant
  • If they can be used in combination with other myeloma drugs
  • If they can they be infused and expanded several times
In a Phase 1 clinical study published in Oncoimmunology,

Spanish researchers used several infusions of expanded NK cells in combination with either bortezomib or lenalidomide. This is the first time this type of study has been performed. The small study included five patients who had received prior treatment. Three were treated with Revlimid and two with Velcade. Myeloma is likely to prevent the natural killer cells from attacking the tumor cells. In an effort to re-activate this normal function, researchers extracted NK cells from patients then put them together with lab-grown leukemia cells for several weeks. In the presence of the other cells, the NK cells regained their activity. Four patients received two infusions each and one patient received four infusions. According to the study results, four out of the five patients obtained disease stabilization before the end of the treatment. Two of the five had a 50% reduction in bone marrow infiltration and a long term response of over a year. Infused NK cells were detected in the bone marrow and blood after the infusions. Patients did not experience any major complications. The number of active NK cells in patients' blood increased by 15.2% for those taking Velcade and .4 percent for those taking Revlimid. To find all clinical trials using NK cells, click here: NK Cell Myeloma Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube